Ottozole

OTULFI for Psoriasis and Arthritis Treatment

OTULFI is a biosimilar to STELARA, designed to treat moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn’s disease. It works by inhibiting interleukin-12 and -23, which helps reduce inflammation and alleviate symptoms.

Indications:

• Plaque Psoriasis: OTULFI is indicated for adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
• Psoriatic Arthritis: It is used to treat active psoriatic arthritis in adults and pediatric patients 6 years and older.
• Crohn’s Disease: OTULFI is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease.

Dosage:

• Plaque Psoriasis: For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients weighing more than 100 kg, the initial dosage is 90 mg, followed by 90 mg every 12 weeks.
• Psoriatic Arthritis: The dosage regimen is similar to that for plaque psoriasis.
• Crohn’s Disease: The recommended dosage is 130 mg administered via intravenous infusion.

Administration:

• OTULFI can be administered subcutaneously or intravenously..
• For subcutaneous administration, it is given at Weeks 0 and 4, then every 12 weeks thereafter..
• For intravenous infusion, it is given as a 130 mg dose..

Important Considerations:

• Avoid initiating treatment with OTULFI in patients with any clinically important active infection until the infection resolves or is adequately treated..
• Consider the risks and benefits of treatment prior to initiating use in patients with a chronic infection or a history of recurrent infection..

OTULFI is a reliable option for managing various inflammatory conditions, offering a convenient and effective treatment regimen. Consult with your healthcare provider to determine if OTULFI is right for you.